IP Library Granted Patent US 8,828,956
Granted Patent B2
US 8,828,956 · App. 13/693,478 · Granted Sep 9, 2014

Carbohydrate conjugates as delivery agents for oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,828,956
App. No.
13/693,478
Granted
Sep 9, 2014
Kind
B2
Abstract

The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

Claims (32)

1. A modified RNA agent comprising a structure shown below:

wherein:

L G is independently for each occurrence a ligand; and

all of the nucleotide sugars of the modified RNA agent are modified.

2. A modified RNA agent comprising a structure shown in formula (II) -(V):

wherein:

q 2A , q 2B , q 3A , q 3B , q 4A , q 4B , q 5A , q 5B and q 5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

P 2A , P 2B , P 3A , P 3B , P 4A , P 4B , P 5A , P 5B , P 5C , T 2A , T 2B , T 3A , T 3B , T 4A , T 4B , T 5A , T 5B , and T 5C are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH 2 , CH 2 NH or CH 2 O;

Q 2A , Q 2B , Q 3A , Q 3B , Q 4A , Q 4B , Q 5A , Q 5B , and Q 5C are independently for each occurrence absent, alkylene, substituted alkylene wherin one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO 2 , N(R N ), C(R′)═C(R″), C≡C or C(O);

R 2A , R 2B , R 3A , R 3B , R 4A , R 4B , R 5A , R 5B , and R 5C are each independently for each occurrence absent, NH, O, S, CH 2 , C(O)O, C(O)NH, NHCH(R a )C(O), —C(O)—CH(R a )—NH—, CO, CH═N—O,

 or heterocyclyl;

L 2A , L 2B , L 3A , L 3B , L 4A , L 4B , L 5A , L 5B and L 5C are each independently for each occurrence a carbohydrate;

R′ and R″ are each independently H, C 1 -C 6 alkyl, OH, SH or N(R N ) 2 ;

R N is independently for each occurrence methyl, ethyl, propyl, isopropyl, butyl or benzyl; and

R a is H or amino acid side chain,

wherein all of the nucleotide sugars of the modified RNA agent are modified.

3. The modified RNA agent of claim 1 , wherein the modified RNA agent is double stranded.

4. The modified RNA agent of claim 3 , wherein the structure is at the 3′-end of one of the strands.

5. The modified RNA agent of claim 4 , wherein the structure is at the 3′-end of the sense strand.

6. The modified RNA agent of claim 1 , wherein the structure is

7. The modified agent of claim 1 , wherein the structure is

8. A modified RNA agent comprising a structure of

wherein all of the nucleotide sugars of the modified RNA agent are modified.

9. A modified RNA agent comprising a structure of

wherein all of the nucleotide sugars of the modified RNA agent are modified.

10. The modified RNA agent of claim 1 , wherein L G is carbohydrate.

11. The modified RNA agent of claim 10 , wherein the carbohydrate is selected from the group consisting of monosaccharide, disaccharide, trisaccharide, tetrasaccharide and polysaccharide.

12. The modified RNA agent of claim 1 , wherein L G is galactose or N-acetylgalactosamine.

13. The modified RNA agent of claim 1 , wherein the nucleotide sugars of the modified RNA agent are modified at the 2′ position to replace 2′ hydroxyl.

14. The modified RNA agent of claim 13 , wherein the 2′ hydroxyl is replaced with a moiety selected from the group consisting of 2′-methoxyethyl, 2′-OCH 3 , 2′—O-allyl, 2′—C-allyl, and 2′-fluoro.

15. A method of modulating the expression of a target gene in a cell, comprising providing to said cell a modified RNA agent of claim 1 .

16. A pharmaceutical composition comprising a modified RNA agent of claim 1 alone or in combination with a pharmaceutically acceptable carrier or excipient.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2022
From: NARAYANNAIR, JAYAPRAKASH K.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 058940/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2022
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; JAYPRAKASH, NARAYANANNAIR K.; MAIER, MARTIN
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 058794/0339 →